Publicacions en què col·labora amb David Navarro Ortega (21)

2023

  1. Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study

    Journal of medical virology, Vol. 95, Núm. 7, pp. e28933

  2. Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors

    British Journal of Haematology, Vol. 200, Núm. 6, pp. e58-e61

  3. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

    Blood Cancer Journal, Vol. 13, Núm. 1

  4. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

    Viruses, Vol. 15, Núm. 10

2022

  1. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

    American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42

2021

  1. Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group

    Transplant Infectious Disease, Vol. 23, Núm. 4

  2. Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib

    British Journal of Haematology

2017

  1. IL28B genetic variation and cytomegalovirus-specific T-cell immunity in allogeneic stem cell transplant recipients

    Journal of Medical Virology, Vol. 89, Núm. 4, pp. 685-695

2016

  1. Efficacy and safety of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic stem cell transplant recipients

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

2015

  1. Cytomegalovirus infection management in allogeneic stem cell transplant recipients: A national survey in Spain

    Journal of Clinical Microbiology, Vol. 53, Núm. 8, pp. 2741-2744

  2. Enumeration of NKG2C+ natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of cytomegalovirus DNAemia

    Journal of Medical Virology, Vol. 87, Núm. 9, pp. 1601-1607

  3. Functional patterns of cytomegalovirus (CMV) pp65 and immediate early-1-specific CD8+ T cells that are associated with protection from and control of CMV DNAemia after allogeneic stem cell transplantation

    Transplant Infectious Disease, Vol. 17, Núm. 3, pp. 361-370

2014

  1. An evaluation of the role of NKG2C+ natural killer cells in protection from cytomegalovirus DNAemia early following allogeneic stem cell transplantation

    Journal of Medical Virology, Vol. 86, Núm. 5, pp. 806-811

2012

  1. Functional profile of cytomegalovirus (CMV)-specific CD8 + T cells and kinetics of NKG2C + NK Cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients

    Journal of Medical Virology, Vol. 84, Núm. 2, pp. 259-267

2011

  1. Effect of cytomegalovirus (CMV) serostatus on the incidence and virological features of active CMV infection in allogeneic stem cell transplant recipients

    Clinical Infectious Diseases

  2. Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8+ and CD4 + T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT

    Bone Marrow Transplantation, Vol. 46, Núm. 11, pp. 1437-1443

  3. Surveillance for adenovirus DNAemia early after transplantation in adult recipients of unrelated-donor allogeneic stem cell transplants in the absence of clinically suspected infection

    Bone Marrow Transplantation

2010

  1. An Assessment of the Effect of Human Herpesvirus-6 Replication on Active Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation

    Biology of Blood and Marrow Transplantation, Vol. 16, Núm. 5, pp. 653-661

  2. Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNγ CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: Potential implications for the management of active CMV infection

    Journal of Medical Virology, Vol. 82, Núm. 7, pp. 1208-1215

  3. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFN CD8 and CD4 T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients

    Bone Marrow Transplantation, Vol. 45, Núm. 3, pp. 543-549